Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Tirzepatide (Mounjaro, Zepbound) represents a breakthrough in type 2 diabetes and weight management as the first dual GIP/GLP-1 receptor agonist approved by the FDA
Tirzepatide frequently causes nausea, vomiting, diarrhea, and decreased appetite, particularly during dose initiation and escalation
It also covers a family history of familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer, or a first-degree relative (parent, sibling, or child) diagnosed with colorectal cancer or an adenomatous polyp
L.Ortega-VillasanteC.et al
US$ 27.11
US$ 23.31
US$ 24.32
US$ 29.48
US$ 26.06
